Translational Research

In this issue, the article on the Functional Status of ras and p53 Mutations in Human Cancer describes how advances in the understanding of cell biology may be relevant to the treatment of cancer. Furthermore, highlights from the Oncology 2000 meeting on Molecular Monitoring of Tumour Response demonstrate that sensitive molecular tumour markers may now be possible to quantify the status of clinically undetectable disease. These are just two examples of how advances in basic science and clinical practice can be bridged by translational research.

In the next decade, the development of novel diagnostic tests and new therapeutics using valid and rigorous methods of clinical trials will define the role of new forms of treatment for cancer. One successful example is the use of the monoclonal antibody to the Her2 receptor in the treatment of breast cancer. Novel anticancer strategies are increasingly designed from improved understanding of basic tumour biology. Scientists and clinicians are no longer working in the separate worlds of laboratories and the bed-side. The challenging field of translational research will no doubt continue to expand and impact upon clinical practice and benefit patients.

Professor Anthony TC Chan

Deputy Editor